In 2017, Kite received approval for Yescarta, designed to treat lymphoma. Juno then sued Kite, alleging it used research patented by Memorial Sloan Kettering Cancer Center and licensed by Juno to develop Yescarta.
After two years of litigation, the U.S. District Court for the Central District of California in Los Angeles ordered Kite to pay $752 million to Juno and Memorial Sloan, declaring that it did violate the research patent Juno had licensed.
The payment includes $585 million in damages as well as 27.6 percent of running royalty on sales of Yescarta, which totaled $264 million in 2018, according to MedCity News.
Gilead acquired Kite for $11.9 billion in 2017. The drug giant told MedCity News in a statement Dec. 13: “We remain steadfast in our opinion that Sloan Kettering’s patent is infringed and is invalid. Given that Kite independently developed Yescarta and assumed all of the risk in its discovery and development, we do not believe Sloan Kettering and Juno are entitled to any level of damages.”
An investment analyst told MedCity News that investors expect Gilead to divest Kite, and CEO Daniel O’Day reportedly said Gilead would have Kite operate as a separate business.
Read the full article here.
More articles on pharmacy:
House passes Pelosi’s drug pricing bill, with a few changes
Walmart agrees to continue accepting paper prescriptions
Sienna Biopharmaceuticals to shut down by end of week
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
